Loading stock data…
NUVL
$99.04-1.24 (-1.24%)
Market ClosedLast close May 1
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvalent, Inc. in the Healthcare sector is trading at $99.04. The stock is currently 12% below its 52-week high of $113.02, remaining 4.3% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why NUVL maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$99.04
Potential Upside
5%
Whystock Fair Value$103.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$142.37+43.8%
Range$116.00 – $165.00
Fundamentals
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5.85%
Volume
Today's trading volume
397,544
Recent News
Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC
Nuvalent (NASDAQ:NUVL) is one of the best up and coming stocks with highest upside potential. On April 7, Nuvalent submitted an NDA to the FDA for neladalkib, its investigational ALK-selective inhibitor for patients with advanced ALK-positive non-small cell lung cancer/NSCLC who have previously been treated with tyrosine kinase inhibitors/TKIs. This submission comes less than four […]
Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data
Nuvalent (NUVL) is back in focus after fresh clinical and regulatory updates for its cancer pipeline, including FDA review progress for zidesamtinib and new trial data to be spotlighted at major oncology meetings. See our latest analysis for Nuvalent. The latest FDA milestones and conference data sit alongside a 12.35% 1 month share price return and a very large 3 year total shareholder return, suggesting momentum around Nuvalent’s cancer pipeline and shifting expectations for future risk and...
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL)
Nuvalent, Inc. recently reported new clinical and preclinical data for its investigational ROS1-selective inhibitor zidesamtinib at the AACR 2026 meeting, alongside confirmation that the FDA has accepted its NDA to treat previously ROS1 TKI-treated adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, with a PDUFA action date set for September 18, 2026. This combination of fresh efficacy and brain penetrance data with a formal regulatory review timeline marks a...
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.